AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00833443 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupropion
Description: Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days. The medication treatment phase is for 12 weeks.
Study NCT00833443 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Bupropion
Description: Bupropion dose will start at 150 mg per day (one 150 mg sustained release tablet per day) for days 1-3 of the first week. The dose will then be increased to 300 mg per day (one 150 mg sustained release tablet twice daily) on day 4 and will remain 300 mg per day until the last week of the medication phase, when the dose will be decreased to 150 mg per day (one 150 mg sustained release tablet per day) for the last three days. The medication treatment phase is for 12 weeks.
Study NCT00222144 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gleevec and Taxotere
Description: Gleevec 600 mg QD for 12 months Taxotere IV 30 mg/m2 on day 1, 8 and 15
Study NCT03931226 — intervention group
Intervention type: DRUG
Intervention: Drug consumption
Description: number of Daily Defined Doses (DDDs) of medications prescribed and given to children in connection with the indication of the spa treatment
Study NCT04061109 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant Human Coagulation FVIII
Description: A kind of Recombinant Coagulation Factor VIII Injection produced by sponsor.
Study NCT03988426 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Octanorm
Description: Octanorm
Study NCT02176629 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Condition virtual reality (VR) then Condition classic cognitive stimulation (CCS)
Study NCT02176629 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Condition classic cognitive stimulation (CCS) then Condition virtual reality (VR)
Study NCT01734824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Denosumab
Description: sc RANKL-inhibitor
Study NCT01734824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Teriparatide
Description: daily subcutaneous injection of teriparatide
Study NCT01734824 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo Denosumab
Description: one subcutaneous injection denosumab placebo
Study NCT01734824 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Teriparatide
Description: daily subcutaneous placebo injection
Study NCT05595343 — intervention group
Intervention type: PROCEDURE
Intervention: Laparoscopic distal pancreatectomy
Description: Comparison of performed laparoscopic distal pancreas surgery in two different surgeon groups
Study NCT04389866 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: JUVÉDERM VOLUMA™ XC
Description: Injectable gel
Study NCT02663336 — intervention group
Intervention type: OTHER
Intervention: Comparison ABPM with OBPM
Description: No interventions
Study NCT03661177 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sovereign nation diet
Description: We will pilot a RCT with delayed intervention to provisionally assess health impacts of consuming a diet that is 50% indigenous foods for four weeks.
Study NCT02251496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: In between meals snacks (Snacks-group)
Description: In between meals snacks (Snacks-group): The subjects in this group will be provided with and encouraged to select in-between-meals snacks providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
Study NCT02251496 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Oral nutrition supplement (ONS-group)
Description: The subjects in this group will be provided with and encouraged to take two ready to drink oral nutrition supplements (ONS) daily, providing \~ 600 kcal/d in addition to the hospital food (during hospitalisation) or in addition to their daily diet at home (after discharge from the hospital).
Study NCT02525640 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hearing Aid
Description: Hearing aid comparison
Study NCT02613195 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrogen-Rich Celsior Solution
Description: Before the procedure, add hydrogen gas into Celsior solution. After harvesting the liver/kidney grafts, lavage and cold store the grafts with Hydrogen-Rich Celsior Solution.
Study NCT04391855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tramadol with ropivacaine
Description: A solution of tramadol 2mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
Study NCT04391855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine with ropivacaine
Description: A solution of dexmedetomidine 1μg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
Study NCT04391855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Magnesium with ropivacaine
Description: A solution of magnesium 10 mg/kg with ropivacaine hydrochloride (10mg/ml) 100mg mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
Study NCT04391855 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ropivacaine plus normal saline
Description: A solution of ropivacaine hydrochloride (10mg/ml) 100mg with 5ml of isotonic saline 0.9% mixture making up a total volume of 15ml will be infiltrated in the surgical trauma area before closure.
Study NCT04179786 — intervention group
Intervention type: BIOLOGICAL
Group type: OTHER
Intervention: Sci-B-Vac™
Description: Sci-B-Vac™ is a recombinant Hepatitis B vaccine, produced by SciVac Israel Ltd under good manufacturing practices (GMP). It contains the 3 surface antigens of the Hepatitis B virus: HBs, pre-S1 and pre-S2. Each 1 ml dose contains sterile 10 μg Hepatitis B virus surface antigens. It is formulated for intramuscular injection supplied in single use vials containing 1ml suspension.
Study NCT01655238 — intervention group
Intervention type: OTHER
Intervention: BMI
Description: Screening guideline to assess body mass index.
Study NCT02681081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Glucose Administration
Description: For sessions 2 through 4, participants will fast for two hours prior to each session and consume 25-30 g of glucose at the start of each session.
Study NCT02681081 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent Fasting
Description: For sessions 2 through 4, participants will fast for 16 hours prior to the session (no food or beverages other than non-caloric beverages or coffee after 6 or 7 pm the evening prior).
Study NCT02681081 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: Normal food intake
Study NCT02606318 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Adjusted the challenge-skill balance
Description: In the first session of occupational therapy, the therapist assessed the client's problems in daily living using the Canadian Occupational Performance Measure. Based on the problems identified, an activity that could be supported in day care was selected. In the second session, the client performed the selected activity, and then the challenge and skill levels of the activity were evaluated. Based on these levels, adjustment of the challenge-skill balance in the activity was attempted. Occupational therapy consisted of 10 sessions of 20 minutes held over about 10 weeks
Study NCT02606318 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Non-adjusted the challenge-skill balance
Description: The first and second sessions were conducted in the same way as for the experimental group, except that the therapists were not informed of the client's subjective perception of the challenge and skill levels for the activity. From the third session, the therapists simply assessed the client's performance and conducted the therapy in the normal manner for the day care center, following the general guidelines for occupational therapy practice
Study NCT01541865 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Renal Denervation
Description: percutaneous renal denervation using the Vessix RF balloon catheter
Study NCT03046836 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxytocin
Description: 40 IU oxytocin nasal spray
Study NCT03046836 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Saline
Study NCT01476410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Given IV
Study NCT01476410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin hydrochloride
Description: Given IV
Study NCT01476410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vinblastine
Description: Given IV
Study NCT01476410 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dacarbazine
Description: Given IV
Study NCT01476410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: quality-of-life assessment
Description: Ancillary studies
Study NCT01476410 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DNA analysis
Description: Optional correlative studies
Study NCT01476410 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: RNA analysis
Description: Optional correlative studies
Study NCT01476410 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: fludeoxyglucose F 18
Description: Correlative studies
Study NCT01476410 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: positron emission tomography
Description: Correlative studies
Study NCT01476410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT01476410 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: immunohistochemistry staining method
Description: Optional correlative studies
Study NCT01476410 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: polymorphism analysis
Description: Optional correlative studies
Study NCT03141255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: IVTM™ System
Description: TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
Study NCT03141255 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Quattro® Catheter
Description: TH will be initiated and maintained for 24 hours using the IVTM™ System and the Quattro® Catheter. After 24 hours of maintained TH, patients will be rewarmed to normal body temperature using the same Quattro® Catheter.
Study NCT02240121 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rifaximin EIR
Description: Rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
Study NCT02240121 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
Study NCT02213068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: belatacept
Description: Please reference Arm description for belatacept + MPA and Arm description for Arm belatacept + Low-Dose Tac for details on this intervention
Study NCT02213068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: belatacept
Description: Please reference Arm description for belatacept + MPA and Arm description for Arm belatacept + Low-Dose Tac for details on this intervention
Study NCT02213068 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Tacrolimus
Description: Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + Low-Dose Tac for details on this intervention
Study NCT02213068 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + Low-Dose Tac for details on this intervention
Study NCT02213068 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: MPA
Description: Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + MPA for details on this intervention
Study NCT02213068 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MPA
Description: Please see Arm Descriptions for both Standard of Care Arm Tacrolimus + MPA standard treatment regimen and belatacept + MPA for details on this intervention
Study NCT02797912 — intervention group
Intervention type: OTHER
Intervention: No intervention
Study NCT04137419 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotic lozenges
Description: Probiotic strains
Study NCT04137419 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Similar to ProlacSan lozenges in taste in colour
Study NCT03764579 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: sleep and diet intervention vs diet intervention
Description: lifestyle healthy food and use Harvard plate and reduce use electronic device prior sleep.
Study NCT04586556 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Polyps detection by Artificial Intelligence
Description: The AI system will capture the live video of the procedure and the AI feedback (polyp detection, tracking, and pathology prediction) will be shown on a second screen installed next to the regular endoscopy screen. Screen A will show the regular endoscopy image and screen B will show the regular endoscopy image together with the areas that might harbor a polyp or the information to predict pathology
Study NCT02111512 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Administration of Live attenuated influenza vaccine (LAIV)
Study NCT04228562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: non-modifiable factor
Description: the presence of an uncontrollable / unremovable risk factor for a disease
Study NCT00158756 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo for the Rotarix™ vaccine
Study NCT02067143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prephase PDN + CY
Study NCT00158756 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Placebo for the Rotarix™ vaccine
Study NCT01319773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine ophthalmic emulsion Formulation A
Description: One drop of cyclosporine ophthalmic emulsion Formulation A administered to each eye twice daily for 2 days and once in the morning of Day 3.
Study NCT01319773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine ophthalmic emulsion Formulation B
Description: One drop of cyclosporine ophthalmic emulsion Formulation B administered to each eye twice daily for 2 days and once in the morning of Day 3.
Study NCT01319773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion 0.05%
Description: One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
Study NCT01319773 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: cyclosporine ophthalmic emulsion Formulation B; cyclosporine ophthalmic emulsion 0.05%
Description: One drop of cyclosporine ophthalmic emulsion Formulation B administered to one eye and one drop of cyclosporine ophthalmic emulsion 0.05% administered to the opposite eye, twice daily for 1 day.
Study NCT01319773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclosporine ophthalmic emulsion Formulation A; cyclosporine ophthalmic emulsion Formulation B
Description: One drop of cyclosporine ophthalmic emulsion Formulation A administered to one eye and one drop of cyclosporine ophthalmic emulsion Formulation B administered to the opposite eye, twice daily for 1 day.
Study NCT03822832 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 655130
Description: Solution for infusion
Study NCT03822832 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Solution for infusion
Study NCT04023903 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bardoxolone methyl
Description: Bardoxolone methyl 5 mg capsules
Study NCT01145430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT01145430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Liposomal Doxorubicin Hydrochloride
Description: Given IV
Study NCT01145430 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies
Study NCT01145430 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Veliparib
Description: Given PO
Study NCT04158661 — intervention group
Intervention type: PROCEDURE
Intervention: thymectomy (robotic-assisted thoracoscopic, minimally-invasive thymectomy)
Description: preferring one unilateral access and placing three trocars between 3rd and 5th intercostal space in a triangular configuration, with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
Study NCT04158661 — intervention group
Intervention type: PROCEDURE
Intervention: thymectomy by means of median sternotomy (transsternal)
Description: with a goal of an en bloc resection of all mediastinal tissue that could anatomically contain gross or microscopic thymus (or both).
Study NCT04158661 — intervention group
Intervention type: PROCEDURE
Intervention: no thymectomy (control)
Description: routine medical care
Study NCT02775474 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Use of Intraoperative Intravenous Methadone
Description: The intervention group will be given intravenous methadone at a fixed induction dose (0,15 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
Study NCT02775474 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Use of Intraoperative Intravenous Fentanyl
Description: The active control group will be given intravenous fentanyl at a fixed induction dose (6 mg / kg) and intraoperative boluses as judged necessary by the anesthesiologist
Study NCT03663439 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: modified shell technique
Description: divided block of bone into two shells and grafting one shell in anterior maxilla
Study NCT03663439 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: modified shell technique
Description: divided block of bone into two shells and grafting one shell in anterior maxilla
Study NCT01551225 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Escitalopram
Description: Patients will start at a dosage of 5 mg daily of escitalopram. After the first week of treatment the dosage will be increased to 10 mg daily. During the visits, the dosage can be gradually increased to a maximum of 20 mg daily, depending on the response of the patient.
Study NCT01551225 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Escitalopram
Description: Patients will start at a dosage of 5 mg daily of escitalopram. After the first week of treatment the dosage will be increased to 10 mg daily. During the visits, the dosage can be gradually increased to a maximum of 20 mg daily, depending on the response of the patient.
Study NCT01335386 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: KLYX
Study NCT01335386 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glycerine
Study NCT02694471 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: physical inactivity or bed rest with supervised recovery
Description: All (older and younger) participants underwent 14 day of horizontal bed rest with all 24 hour daily activities were performed lying in a bed. Maximal one pillow was allowed. 28-day supervised recovery was performed 3 times weekly for 75 minutes/session.
Study NCT02694471 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: physical inactivity or bed rest with supervised recovery
Description: All (older and younger) participants underwent 14 day of horizontal bed rest with all 24 hour daily activities were performed lying in a bed. Maximal one pillow was allowed. 28-day supervised recovery was performed 3 times weekly for 75 minutes/session.
Study NCT02683265 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aptensio XR
Description: Optimized dose of Aptensio XR (10, 15, 20, 30 or 40 mg) administered orally, once daily
Study NCT02683265 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo capsules
Study NCT01102374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: High Dose Vitamin D
Description: Vitamin D3 100,000 IU monthly
Study NCT02067143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycle 1 Induction
Study NCT02067143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycle 2 Induction / Early consolidation
Study NCT02067143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycle 3 Early consolidation
Study NCT02067143 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cycle 4 Consolidation